GOLDMAN SACHS GROUP INC - NURIX THERAPEUTICS INC ownership

NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of NURIX THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$9,694,261
+33.9%
464,507
-5.7%
0.00%
+100.0%
Q1 2024$7,242,191
+148.9%
492,666
+74.8%
0.00%0.0%
Q4 2023$2,909,208
+1.8%
281,900
-22.5%
0.00%0.0%
Q3 2023$2,857,314
-11.4%
363,526
+12.7%
0.00%0.0%
Q2 2023$3,223,253
-32.9%
322,648
-40.3%
0.00%0.0%
Q1 2023$4,801,504
-29.7%
540,710
-13.0%
0.00%
-50.0%
Q4 2022$6,825,695
+63388.9%
621,648
-24.7%
0.00%
-33.3%
Q3 2022$10,751
+155.7%
825,079
+148.6%
0.00%
+200.0%
Q2 2022$4,204
-99.9%
331,843
+5.1%
0.00%0.0%
Q1 2022$4,423,000
-50.5%
315,666
+2.3%
0.00%
-50.0%
Q4 2021$8,931,000
+139.0%
308,487
+147.4%
0.00%
+100.0%
Q3 2021$3,737,000
-49.8%
124,715
-55.6%
0.00%
-50.0%
Q2 2021$7,451,000
-31.0%
280,852
-19.1%
0.00%
-33.3%
Q1 2021$10,791,000
+105.7%
347,093
+117.5%
0.00%
+200.0%
Q4 2020$5,246,000159,5490.00%
Other shareholders
NURIX THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
TRV GP III, LLC 3,422,549$90,800,00015.85%
Ponoi II Management, LLC 686,274$18,207,00014.76%
Ponoi Management, LLC 686,274$18,207,00010.12%
Foresite Capital Management V, LLC 451,522$11,979,0004.71%
Foresite Capital Management IV, LLC 1,205,798$31,990,0004.32%
Bain Capital Life Sciences Investors, LLC 1,284,314$34,073,0002.23%
EcoR1 Capital, LLC 1,967,950$52,210,0001.95%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 571,212$15,155,0001.93%
DAFNA Capital Management LLC 306,320$8,127,0001.70%
Euclidean Capital LLC 154,426$4,097,0001.33%
View complete list of NURIX THERAPEUTICS INC shareholders